Replimune Group Inc
REPL10.090USD
+0.370+3.81%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
791.09MMarket Cap
LossP/E TTM
More Details of Replimune Group Inc Company
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Replimune Group Inc Info
Ticker SymbolREPL
Company nameReplimune Group Inc
IPO dateJul 20, 2018
CEOPatel (Sushil)
Number of employees479
Security typeOrdinary Share
Fiscal year-endJul 20
Address500 Unicorn Park Dr
CityWOBURN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01801-3377
Phone17812229600
Websitehttps://www.replimune.com/
Ticker SymbolREPL
IPO dateJul 20, 2018
CEOPatel (Sushil)
Company Executives of Replimune Group Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Philip Astley-Sparke
Mr. Philip Astley-Sparke
Executive Chairman of the Board
Executive Chairman of the Board
1.32M
+5.99%
Dr. Sushil Patel, Ph.D.
Dr. Sushil Patel, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
71.28K
-12.30%
Ms. Emily Luisa Hill
Ms. Emily Luisa Hill
Chief Financial Officer
Chief Financial Officer
27.70K
-24.84%
Dr. Konstantinos Xynos, M.D.
Dr. Konstantinos Xynos, M.D.
Chief Medical Officer
Chief Medical Officer
26.69K
-21.36%
Mr. Christopher (Chris) Sarchi
Mr. Christopher (Chris) Sarchi
Chief Commercial Officer
Chief Commercial Officer
22.67K
-18.68%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Independent Director
Independent Director
6.67K
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Mr. Dieter Weinand
Mr. Dieter Weinand
Lead Independent Director
Lead Independent Director
--
--
Ms. Veleka Peeples-Dyer
Ms. Veleka Peeples-Dyer
Independent Director
Independent Director
--
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Philip Astley-Sparke
Mr. Philip Astley-Sparke
Executive Chairman of the Board
Executive Chairman of the Board
1.32M
+5.99%
Dr. Sushil Patel, Ph.D.
Dr. Sushil Patel, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
71.28K
-12.30%
Ms. Emily Luisa Hill
Ms. Emily Luisa Hill
Chief Financial Officer
Chief Financial Officer
27.70K
-24.84%
Dr. Konstantinos Xynos, M.D.
Dr. Konstantinos Xynos, M.D.
Chief Medical Officer
Chief Medical Officer
26.69K
-21.36%
Mr. Christopher (Chris) Sarchi
Mr. Christopher (Chris) Sarchi
Chief Commercial Officer
Chief Commercial Officer
22.67K
-18.68%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Independent Director
Independent Director
6.67K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
14.08%
T. Rowe Price Associates, Inc.
10.42%
RTW Investments L.P.
8.15%
BlackRock Institutional Trust Company, N.A.
6.36%
Forbion Capital Partners
5.30%
Other
55.68%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
14.08%
T. Rowe Price Associates, Inc.
10.42%
RTW Investments L.P.
8.15%
BlackRock Institutional Trust Company, N.A.
6.36%
Forbion Capital Partners
5.30%
Other
55.68%
Shareholder Types
Shareholders
Proportion
Hedge Fund
38.13%
Investment Advisor
32.45%
Investment Advisor/Hedge Fund
23.49%
Research Firm
6.34%
Venture Capital
5.70%
Individual Investor
3.42%
Pension Fund
0.44%
Bank and Trust
0.22%
Insurance Company
0.03%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
385
84.18M
107.31%
-13.74M
2025Q2
375
87.53M
112.61%
-11.65M
2025Q1
385
87.62M
114.03%
-12.35M
2024Q4
379
83.57M
108.59%
-8.22M
2024Q3
364
75.43M
109.54%
-13.17M
2024Q2
356
76.19M
113.04%
-8.45M
2024Q1
339
72.12M
117.78%
-11.10M
2023Q4
328
71.51M
121.06%
+610.98K
2023Q3
311
68.80M
117.09%
+4.78M
2023Q2
308
66.67M
115.61%
+3.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
11.05M
14.15%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
10.69M
13.69%
-37.35K
-0.35%
Jun 30, 2025
RTW Investments L.P.
2.07M
2.65%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.97M
6.37%
-281.41K
-5.36%
Jun 30, 2025
Forbion Capital Partners
3.91M
5.01%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.46M
4.44%
-357.89K
-9.37%
Jun 30, 2025
Tang Capital Management, LLC
3.20M
4.1%
+300.00K
+10.34%
Jun 30, 2025
State Street Investment Management (US)
2.45M
3.14%
+54.64K
+2.28%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.67%
Tema Oncology ETF
0.53%
ALPS Medical Breakthroughs ETF
0.31%
State Street SPDR S&P Biotech ETF
0.26%
T Rowe Price Small-Mid Cap ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Fidelity Enhanced Small Cap ETF
0.14%
iShares Micro-Cap ETF
0.13%
Invesco Nasdaq Biotechnology ETF
0.08%
Avantis US Small Cap Equity ETF
0.07%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.67%
Tema Oncology ETF
Proportion0.53%
ALPS Medical Breakthroughs ETF
Proportion0.31%
State Street SPDR S&P Biotech ETF
Proportion0.26%
T Rowe Price Small-Mid Cap ETF
Proportion0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.16%
Fidelity Enhanced Small Cap ETF
Proportion0.14%
iShares Micro-Cap ETF
Proportion0.13%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
Avantis US Small Cap Equity ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Replimune Group Inc?
The top five shareholders of Replimune Group Inc are:
Baker Bros. Advisors LP holds 11.05M shares, accounting for 14.15% of the total shares.
T. Rowe Price Associates, Inc. holds 10.69M shares, accounting for 13.69% of the total shares.
RTW Investments L.P. holds 2.07M shares, accounting for 2.65% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.97M shares, accounting for 6.37% of the total shares.
Forbion Capital Partners holds 3.91M shares, accounting for 5.01% of the total shares.
Baker Bros. Advisors LP holds 11.05M shares, accounting for 14.15% of the total shares.
T. Rowe Price Associates, Inc. holds 10.69M shares, accounting for 13.69% of the total shares.
RTW Investments L.P. holds 2.07M shares, accounting for 2.65% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.97M shares, accounting for 6.37% of the total shares.
Forbion Capital Partners holds 3.91M shares, accounting for 5.01% of the total shares.
What are the top three shareholder types of Replimune Group Inc?
The top three shareholder types of Replimune Group Inc are:
Baker Bros. Advisors LP
T. Rowe Price Associates, Inc.
RTW Investments L.P.
Baker Bros. Advisors LP
T. Rowe Price Associates, Inc.
RTW Investments L.P.
How many institutions hold shares of Replimune Group Inc (REPL)?
As of 2025Q3, 385 institutions hold shares of Replimune Group Inc, with a combined market value of approximately 84.18M, accounting for 107.31% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.30%.
What is the biggest source of revenue for Replimune Group Inc?
In --, the -- business generated the highest revenue for Replimune Group Inc, amounting to -- and accounting for --% of total revenue.
